emavusertib

Small moleculeexperimental

Clinical trial activity

10 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
8
Phase 2
3
Phase 3
0
Phase 4
0

Earliest trial started Dec 28, 2017 (NCT03328078)

Timeline

2010s

  1. Jan 1, 2017

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2022

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

Cc1cc(-c2nc(C(=O)Nc3cc4oc(N5CCOCC5)nc4nc3N3CC[C@@H](O)C3)co2)ccn1
Mol. weight
491.51 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07271667Phase 2Dec 31, 2025Curis
NCT07107750Phase 1Oct 31, 2025Curis, Washington University in St. Louis
NCT06696768Phase 1Dec 30, 2024National Cancer Institute (NCI), Yale University
NCT06439836Phase 1Dec 16, 2024Mount Sinai Hospital, Canada, National Cancer Institute (NCI)
NCT05669352Phase 1/Phase 2 (Phase 2)Aug 31, 2023Merck, University of Florida
NCT05685602Phase 1Jun 12, 2023National Cancer Institute (NCI), Yale University
NCT05187182Phase 1Nov 30, 2022Curis, Washington University in St. Louis
NCT05178342Phase 2Jan 1, 2022Curis, University of Leipzig
NCT04278768Phase 1Feb 19, 2020Curis
NCT03328078Phase 1Dec 28, 2017Curis
Showing 10 of 10 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
CurisFor profit6322017
National Cancer Institute (NCI)Government3312023
Washington University in St. LouisAcademic/Hospital2212022
Yale UniversityAcademic/Hospital2012023
MerckFor profit1012023
Mount Sinai Hospital, CanadaAcademic/Hospital1012024
University of FloridaAcademic/Hospital1112023
University of LeipzigAcademic/Hospital1112022
8 organizations
Page 1 / 1